Abstract
Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days. Short time cure rate was 97% (cure 71%, improvement 26%) and failure 3%, long time cure rate (six months follow-up) was 74%. Predominant initial pathogens wereHaemophilus influenzae andStreptococcus pneumoniae, mostly in pure cultures. All sputum cultures except those withStreptococcus pneumoniae became negative on the third day of treatment. Apart from a slower clearance of pneumococci from sputum there were no significant differences in responses between pneumococcal andHaemophilus infections during and after therapy. Mild adverse gastrointestinal effects were noticed in five patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoogkamp-Korstanje JAA.In vitro activity of ciprofloxacin. Eur Clin Microbiol 1984;3:333–8.
Morel C, Vergnaud M, Langeard MM, Monrocq N. Pefloxacin-diffusion into the bronchial mucus. 13th International Congress of Chemotherapy, Vienna/1983: Proceedings ps 4.6/4–8.
Nicki Y, Soejima R, MatsushimaT, Kawanashi M, Nakaha C, Wantanabe M. Clinical studies on DL-8280 in the treatment of patients with respiratory tract infections. Chemotherapy (Tokyo) 1984: 32, supplement, 54–8.
Shah PM, Strehl R, Posselt HG, Bender SW. Ciprofloxacin bei Mucoviszidose, eine pharmakokinetische Untersuchung. Fortschr Antimikrobiellen und Antineoplastischen Chemother 1984;3–5:685–90.
Bergogne-Berezin E, Berthelot G, Even P, Dennewald G, Stern M. Pharmacokinetics of ciprofloxacin: study of its distribution in the respiratory secretions. 14th International Congress of Chemotherapy, Kyoto, 1985: S40–10.
Hoogkamp-Korstanje JAA and Klein S. Ciprofloxacin in acute exacerbations of chronic bronchitis. 14th International Congress of Chemotherapy, Kyoto, 1985: S50–1.
Benard Y, Lemenager J, Morel C. Biochemical evaluation of pefloxacin in infectious bronchopulmonary disease. 13th International Congress of Chemotherapy, Vienna, 1983: Proceedings PS 4.6, 4–9.
Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1986;18:407–13.
Mehtar S, Drabu YJ. Non-comparative study of ciprofloxacin in respiratory tract infections. 14th International Congress of Chemotherapy, Kyoto 1985: S50–3.
Bassaris H, Chrysanthopoulos C, Skoutelis A, Politimakrypoulia V. Treatment of pneumonias with ciprofloxacin. 14th International Congress of Chemotherapy, Kyoto: 1985; p.38–94.
Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. J Antimicrob Chemother 1986;18(Suppl d):133–9.
Kobayashi H. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory infection. Am J Med 1987;82:169–74.
Honeyboune D, Wise R, Andrews JM. Ciprofloxacin penetration into lungs. Lancet 1987;i:407–13.
Schlenkhoff D, Mayer M, Dalhoff A. Penetration of ciprofloxacin into human lung tissue following a simple intravenous administration. 14th International Congress of Chemotherapy, Kyoto, 1985: S40–11.
Rubinstein E, Segev S. Drug interactions of ciprofloxacin with other non-antibiotic agents. Am J Med 1987;82:119–23.
Author information
Authors and Affiliations
Additional information
This paper is based on data that have also been published in reference 8.
Rights and permissions
About this article
Cite this article
Hoogkamp-Korstange, J.A.A., Klein, S.J. Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. Pharmaceutisch Weekblad Scientific Edition 9 (Suppl 1), S60–S63 (1987). https://doi.org/10.1007/BF02075263
Issue Date:
DOI: https://doi.org/10.1007/BF02075263